Basic Science and Dialysis: Disturbances of Acquired Immunity in Hemodialysis Patients

Acquired immunity disturbances in hemodialysis (HD) patients are many and diverse. They are caused by uremia per se, the HD procedure, chronic renal failure complications, and therapeutic interventions for their treatment. Current data suggest that acquired immunity disturbances in HD patients concern mainly the T‐lymphocyte and the antigen‐presenting cell (APC). The T‐lymphocyte‐dependent immune response is deficient, predisposing to infections and inadequate response to vaccinations. In addition, APCs are preactivated, which seems to be responsible for the malnutrition–inflammation–atherosclerosis syndrome, and also affects T‐lymphocyte function. At the molecular level it is assumed that the interaction between the APC and the T‐lymphocyte is impaired. This disturbance is likely to concern the signal that results from the interaction between the major histocompatibility complex:peptide complex on APC surfaces and T‐cell receptors on T‐lymphocyte surfaces, or the signal that results from the interaction among the co‐receptors of these two cells. The aim of the present review was to collect and classify the available clinical and experimental data in this area. Although many pieces are still missing from the puzzle, a better understanding of the responsible molecular mechanisms, will potentially lead to increased survival and a better quality of life in HD patients.

[1]  I. Kushner Regulation of the Acute Phase Response by Cytokines , 2015, Perspectives in biology and medicine.

[2]  O. Ringdén,et al.  Lymphocytes from multitransfused uremic patients have poor MLC reactivity. , 2008, Tissue antigens.

[3]  E. Thorsby,et al.  The effect of blood transfusions on renal transplantation. Studies of 395 patients registered for transplantation with a first cadaveric kidney. , 2008, Tissue antigens.

[4]  T. Eleftheriadis,et al.  No effect of serum parathyroid hormone level on antigen presenting cell-dependent T-cell reactivity in hemodialysis patients , 2007, International Urology and Nephrology.

[5]  R. Vanholder,et al.  Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  H. Koyama,et al.  Body fat mass and lean mass as predictors of survival in hemodialysis patients. , 2006, Kidney international.

[7]  N. Vaziri,et al.  Naïve and central memory T-cell lymphopenia in end-stage renal disease. , 2006, Kidney international.

[8]  B. Ritz,et al.  Malnutrition and energy restriction differentially affect viral immunity. , 2006, The Journal of nutrition.

[9]  T. Eleftheriadis,et al.  T-Cell zeta chain expression, phosphorylation and degradation and their role in T-cell signal transduction and immune response regulation in health and disease , 2006 .

[10]  A. Reiss,et al.  Atherosclerosis: Immune and Inflammatory Aspects , 2006, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[11]  M. Rocco,et al.  Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? , 2005, Kidney international.

[12]  T. Eleftheriadis,et al.  The value of serum antilipoarabinomannan antibody detection in the diagnosis of latent tuberculosis in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  P. Aljama,et al.  Lymphocyte Apoptosis: Role of Uremia and Permeability of Dialysis Membrane , 2005, Nephron Clinical Practice.

[14]  B. Rutkowski,et al.  Long-term therapy with recombinant human erythropoietin increases CD8+ T-cell apoptosis in haemodialysis patients. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  I. Karayaylali,et al.  Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients? , 2005, Scandinavian journal of urology and nephrology.

[16]  Joan L. Robinson,et al.  Efficacy of Pneumococcal Immunization in Patients with Renal Disease – What Is the Data? , 2004, American Journal of Nephrology.

[17]  A. Asakawa,et al.  Cancer anorexia-cachexia syndrome: cytokines and neuropeptides , 2004, Current opinion in clinical nutrition and metabolic care.

[18]  W. K. Bolton,et al.  Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin. , 2004, Journal of the American Society of Nephrology : JASN.

[19]  A. Lalvani,et al.  Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. , 2004, Kidney international.

[20]  Mark M Davis,et al.  T cell killing does not require the formation of a stable mature immunological synapse , 2004, Nature Immunology.

[21]  B. Jaber,et al.  Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  B. Walse,et al.  Interplay Between Superantigens and Immunoreceptors , 2004, Scandinavian journal of immunology.

[23]  D. Roelen,et al.  Pretransplant blood transfusions revisited: a role for CD4+ regulatory T cells?1 , 2004, Transplantation.

[24]  T. Eleftheriadis,et al.  Impaired T Cell Proliferation and Zeta Chain Phosphorylation after Stimulation with Staphylococcal Enterotoxin-B in Hemodialysis Patients , 2004, Nephron Clinical Practice.

[25]  Arup K Chakraborty,et al.  The Immunological Synapse Balances T Cell Receptor Signaling and Degradation , 2003, Science.

[26]  L. Szczech,et al.  White blood cells as a novel mortality predictor in haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  R. Poduval,et al.  Tuberculosis screening in dialysis patients--is the tuberculin test effective? , 2003, Clinical nephrology.

[28]  G. London,et al.  Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. , 2003, Kidney international. Supplement.

[29]  B. Jaber,et al.  Defective Interleukin-10 Synthesis by Peripheral Blood Mononuclear Cells among Hemodialysis Patients , 2003, Blood Purification.

[30]  K. Hassan,et al.  The Effect of Erythropoietin Therapy and Hemoglobin Levels on the Immune Response to Engerix-B Vaccination in Chronic Kidney Disease , 2003, Renal failure.

[31]  Mai-Szu Wu,et al.  Extrapulmonary Tuberculosis in Chronic Hemodialysis Patients , 2003, Renal failure.

[32]  F. Port,et al.  Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. , 2002, Kidney international.

[33]  Peter Stenvinkel,et al.  The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  G. Malik,et al.  Eleven years of experience with dialysis associated tuberculosis. , 2002, Clinical nephrology.

[35]  Mark M. Davis,et al.  Direct observation of ligand recognition by T cells , 2002, Nature.

[36]  G. Heine,et al.  A shift in the Th1/Th2 ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end‐stage renal disease , 2002 .

[37]  H. Karakayalı,et al.  Role of parathormone levels on T-cell response in hemodialysis patients. , 2002, Transplantation proceedings.

[38]  T. Georg,et al.  Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. , 2002, Kidney international.

[39]  J. Sugimura,et al.  Long-term graft survival with or without donor-specific transfusion in cyclosporine era in one haplo-identical living-related renal transplant recipients beyond the first year: a 19-year experience. , 2002, The Tohoku journal of experimental medicine.

[40]  F. Sánchez‐Madrid,et al.  Cell adhesion and polarity during immune interactions , 2002, Immunological reviews.

[41]  B. Rutkowski,et al.  Long-term therapy with recombinant human erythropoietin decreases percentage of CD152(+) lymphocytes in primary glomerulonephritis haemodialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  A. Yildiz,et al.  Comparative Effect of Oral Pulse and Intravenous Calcitriol Treatment in Hemodialysis Patients: The Effect on Serum IL-1 and IL-6 Levels and Bone Mineral Density , 2002, Nephron.

[43]  M. Girndt,et al.  The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. , 2001, Kidney international.

[44]  W. Ambrosius,et al.  A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  P. Kimmel,et al.  Biocompatibility of Hemodialysis Membranes: Interrelations between Plasma Complement and Cytokine Levels , 2001, Blood Purification.

[46]  A. Dal Canton,et al.  Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  L. Agodoa,et al.  Etiology of bacterial septicemia in chronic dialysis patients in the United States. , 2001, Clinical nephrology.

[48]  Michael Loran Dustin Role of Adhesion Molecules in Activation Signaling in T Lymphocytes , 2001, Journal of Clinical Immunology.

[49]  P. Aljama,et al.  Role of Adhesion Molecules in Mononuclear Cell Apoptosis Induced by Cuprophan Hemodialysis Membranes , 2001, Nephron.

[50]  K. Nitta,et al.  Analysis of lupus activity in end-stage renal disease treated by hemodialysis. , 2001, Internal medicine.

[51]  R Cornet,et al.  Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  K. Chou,et al.  Tuberculosis in Maintenance Dialysis Patients , 2001, Nephron.

[53]  M. Girndt,et al.  Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. , 2001, Kidney international.

[54]  J. Im,et al.  Tuberculosis in patients with end-stage renal disease. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[55]  C. Tetta,et al.  C REACTIVE PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASES , 2001, Renal failure.

[56]  P. Stenvinkel Malnutrition and Chronic Inflammation as Risk Factors for Cardiovascular Disease in Chronic Renal Failure , 2000, Blood Purification.

[57]  K. Chou,et al.  Tuberculin Skin Test and Anergy in Dialysis Patients of a Tuberculosis-Endemic Area , 2000, Nephron.

[58]  B. Jaber,et al.  Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. , 2000, Kidney international.

[59]  E M Walker,et al.  Effects of iron overload on the immune system. , 2000, Annals of clinical and laboratory science.

[60]  C. Zoccali,et al.  Inflammation is associated with carotid atherosclerosis in dialysis patients , 2000, Journal of hypertension.

[61]  M. Girndt,et al.  T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  T. Vachharajani,et al.  Diagnosis and Treatment of Tuberculosis in Hemodialysis and Renal Transplant Patients , 2000, American Journal of Nephrology.

[63]  P. Stenvinkel,et al.  Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[64]  V. Jorgetti,et al.  Immune response in hemodialysis patients: is there any difference when low and high iPTH levels are compared? , 2000, Clinical nephrology.

[65]  Y. Moriyama,et al.  Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. , 2000, Artificial organs.

[66]  M. Girndt,et al.  Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[67]  M. Arias,et al.  B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[68]  T. Greene,et al.  Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. , 2000, Kidney international.

[69]  V. Jorgetti,et al.  Restoration of Impaired T-Cell Proliferation after Parathyroidectomy in Hemodialysis Patients , 2000, Nephron.

[70]  H. DeLuca,et al.  Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. , 1999, The Journal of nutrition.

[71]  S. Kurashige,et al.  Characteristic Cytokine Products of Th1 and Th2 Cells in Hemodialysis Patients , 1999, Nephron.

[72]  J. Tokars,et al.  Tuberculosis in Hemodialysis Patients in New Jersey: A Statewide Study , 1999, Infection Control & Hospital Epidemiology.

[73]  I. Bruce,et al.  Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. , 1999, The Journal of rheumatology.

[74]  N. K. Krane,et al.  Persistent lupus activity in end-stage renal disease. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[75]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[76]  H. Breitbart,et al.  Impaired lymphocyte calcium metabolism in end-stage renal disease: enhanced influx, decreased efflux, and reduced response to mitogen. , 1999, The Journal of laboratory and clinical medicine.

[77]  V. Cantaluppi,et al.  CD40-CD154 interaction in experimental and human disease (review). , 1999, International journal of molecular medicine.

[78]  M. Girndt,et al.  Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[79]  S. Anker,et al.  Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. , 1999, Chest.

[80]  F. Locatelli,et al.  Antiphospholipid (aPL) antibodies in end-stage renal disease. , 1999, Journal of nephrology.

[81]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[82]  J. Fitzgerald,et al.  Risk of tuberculosis in dialysis patients: a population-based study. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[83]  M. Girndt,et al.  Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. , 1998, Journal of the American Society of Nephrology : JASN.

[84]  M. Sever,et al.  Tuberculin responsiveness in hemodialysis patients. , 1998, Chest.

[85]  W. Owen,et al.  C-reactive protein as an outcome predictor for maintenance hemodialysis patients. , 1998, Kidney international.

[86]  D. Serur,et al.  Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[87]  J. Mege,et al.  IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[88]  R. Strawderman,et al.  Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[89]  H. DeLuca,et al.  1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. , 1998, Journal of immunology.

[90]  V. Fraser,et al.  Tuberculosis infection and anergy in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[91]  A. Abbas,et al.  Homeostasis and self-tolerance in the immune system: turning lymphocytes off. , 1998, Science.

[92]  B. Lindholm,et al.  Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. , 1998, Kidney international.

[93]  A. Terashi,et al.  T-cell activation modified by parathyroid hormone (PTH) in patients with end-stage renal disease. , 1997, Clinical nephrology.

[94]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[95]  K. Okasha,et al.  Immunoglobulin G subclasses and susceptibility to allosensitization in humans. , 1997, Clinical nephrology.

[96]  H. Kirchner,et al.  Low efficiency of active immunization against diphtheria in chronic hemodialysis patients. , 1997, Kidney international.

[97]  R. Peces,et al.  Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[98]  M. Newport,et al.  A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. , 1996, The New England journal of medicine.

[99]  D. Birmingham,et al.  Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. , 1996, Kidney international.

[100]  J. Klippel,et al.  End-stage renal disease and systemic lupus erythematosus. , 1996, The American journal of medicine.

[101]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[102]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[103]  M. Girndt,et al.  Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[104]  B. Hoen,et al.  Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[105]  M. Girndt,et al.  Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. , 1995, Kidney international.

[106]  D. Brennan,et al.  Beneficial effects of donor-specific transfusions on long-term renal allograft function. , 1995, Transplantation proceedings.

[107]  P. Jungers,et al.  Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. , 1995, Journal of immunology.

[108]  C. Gasche,et al.  Functional characterization of cytokine autoantibodies in chronic renal failure patients. , 1994, Kidney international.

[109]  R. Vanholder,et al.  Uremic toxicity: the middle molecule hypothesis revisited. , 1994, Seminars in nephrology.

[110]  H. DeLuca,et al.  1α,25-dihydroxyvitamin D3 a nd 19-nor-1α,25-dihydroxyvitamin 32 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo , 1993 .

[111]  A. Sher,et al.  Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[112]  C. Via,et al.  B-cell and T-cell function in systemic lupus erythematosus. , 1993, Current opinion in rheumatology.

[113]  B. Fleischer,et al.  T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. , 1993, Kidney international.

[114]  J. Bergström,et al.  Nutrition and adequacy of dialysis in hemodialysis patients. , 1993, Kidney international. Supplement.

[115]  Corry Rj,et al.  The effect of transfusions on renal allograft survival in the cyclosporine era: a single center report. , 1993 .

[116]  H. DeLuca,et al.  Vitamin D deficiency suppresses cell-mediated immunity in vivo. , 1993, Archives of biochemistry and biophysics.

[117]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[118]  M. Oppermann,et al.  Gene expression of interleukin-1β during hemodialysis , 1993 .

[119]  R. Vanholder,et al.  Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[120]  L. Pączek,et al.  Improved Immunoglobulin Production in Dialysis Patients Treated with Recombinant Erythropoietin , 1992, The International journal of artificial organs.

[121]  D. Churchill,et al.  Canadian Hemodialysis Morbidity Study. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[122]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[123]  O. Götze,et al.  The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. , 1991, Immunology.

[124]  M. Croft,et al.  Helper T‐Cell Subsets: Phenotype, Function and the Role of Lymphokines in Regulating their Development , 1991, Immunological reviews.

[125]  R. Kaempfer,et al.  Regulation of interleukin-2 and interferon-γ gene expression in renal failure , 1991 .

[126]  P. Van der Niepen,et al.  Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. , 1991, Kidney international.

[127]  C. Baldamus,et al.  Immunodeficiency in ESRD-patients is linked to altered IL-2 receptor density on T cell subsets. , 1991, Journal of clinical & laboratory immunology.

[128]  R. Vanholder,et al.  Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. , 1991, Kidney international.

[129]  C. Dinarello,et al.  Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. , 1990, Blood.

[130]  R. Riggio,et al.  Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[131]  J. Berden,et al.  Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis , 1990 .

[132]  E. Ritz,et al.  Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. , 1990, Kidney international.

[133]  T. Tabata,et al.  In vivo Effect of 1α-Hydroxyvitamin D3 on Interleukin-2 Production in Hemodialysis Patients , 1988 .

[134]  E. Ritz,et al.  Cuprammonium membranes stimulate interleukin 1 release and arachidonic acid metabolism in monocytes in the absence of complement. , 1988, Kidney international.

[135]  P. Fondu,et al.  Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. , 1988, The Journal of laboratory and clinical medicine.

[136]  J. Davis,et al.  Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin. , 1988, American journal of epidemiology.

[137]  P. Marckmann Nutritional status of patients on hemodialysis and peritoneal dialysis. , 1988, Clinical nephrology.

[138]  K. Schaefer,et al.  Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. , 1987, The Quarterly journal of medicine.

[139]  S. Meuer,et al.  Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. , 1987, The Journal of clinical investigation.

[140]  C. Pollock,et al.  Dialysis and transplantation in patients with renal failure due to systemic lupus erythematosus. The Australian and New Zealand experience. , 1987, Australian and New Zealand journal of medicine.

[141]  R. Schuurman,et al.  Blood transfusion suppresses cutaneous cell-mediated immunity. , 1986, Clinical and experimental immunology.

[142]  D. de Zeeuw,et al.  Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. , 1985, Nephron.

[143]  J. Vanherweghem,et al.  Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: the critical role of iron overload. , 1985, British medical journal.

[144]  J. Cameron,et al.  End-stage renal failure in systemic lupus erythematosus with nephritis. , 1984, Clinical nephrology.

[145]  W. Szmuness,et al.  Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. , 1984, The New England journal of medicine.

[146]  S. Teitelbaum,et al.  Parathyroid hormone receptors in circulating human mononuclear leukocytes. , 1984, The Journal of biological chemistry.

[147]  J. Kopple,et al.  Nutritional status and lymphocyte function in maintenance hemodialysis patients. , 1984, The American journal of clinical nutrition.

[148]  K. Kamata,et al.  Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components. , 1983, Clinical and experimental immunology.

[149]  B. Descamps-Latscha,et al.  In vitro suppression of cell-mediated immunity by ferroproteins and ferric salts. , 1983, Cellular immunology.

[150]  D. Klatzmann,et al.  SUPPRESSION OF LYMPHOCYTE REACTIVITY BY BLOOD TRANSFUSIONS IN UREMIC PATIENTS: I. PROLIFERATIVE RESPONSES , 1983, Transplantation.

[151]  N. Coplon,et al.  The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. , 1983, The New England journal of medicine.

[152]  H. Sakagami,et al.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[153]  E. Friedman,et al.  Intact antibody response to pneumococcal capsular polysaccharides in uremia and diabetes. , 1980, JAMA.

[154]  A. Polliack,et al.  Suppressive Effect of Ferritin on in Vitro Lymphocyte Function , 1979, British journal of haematology.

[155]  J. Soulillou,et al.  BENEFICIAL EFFECT OF BLOOD TRANSFUSION: ROLE OF THE TIME INTERVAL BETWEEN THE LAST TRANSFUSION AND TRANSPLANTATION1 , 1979, Transplantation.

[156]  R. Sampliner The duration of hepatitis B surface antigenemia. , 1979, Archives of internal medicine.

[157]  E. Lustbader,et al.  Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. , 1977, Kidney international.

[158]  P. Terasaki,et al.  PROLONGATION EFFECT OF BLOOD TRANSFUSIONS ON KIDNEY GRAFT SURVIVAL , 1976, Transplantation.

[159]  K. Nolph,et al.  Antibodies to nuclear antigens in patients undergoing long-term hemodialysis. , 1976, The American journal of medicine.

[160]  G. Barsotti,et al.  Toxicity arising from guanidine compounds: role of methylguanidine as a uremic toxin. , 1975, Kidney international. Supplement.

[161]  M. K. Mann,et al.  Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers. , 1974 .

[162]  J. Sanford,et al.  Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. , 1971, The Journal of clinical investigation.

[163]  Hirokazu Honda,et al.  Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[164]  P. Rautenberg,et al.  Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination , 2005, Infection.

[165]  P. Aljama,et al.  Monocytes from dialysis patients exhibit characteristics of senescent cells: does it really mean inflammation? , 2005, Contributions to nephrology.

[166]  K. Kalantar-Zadeh,et al.  A low lymphocyte percentage is a predictor of mortality and hospitalization in hemodialysis patients. , 2005, Clinical nephrology.

[167]  J. Potter,et al.  Blood pressure in acute stroke. , 2004, Age and ageing.

[168]  Fang Hc,et al.  Tuberculosis in patients with end-stage renal disease. , 2004 .

[169]  G. Heine,et al.  A shift in the Th(1)/Th(2) ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end-stage renal disease. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[170]  J. Wauters,et al.  Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[171]  M. Herselman,et al.  Protein-energy malnutrition as a risk factor for increased morbidity in long-term hemodialysis patients. , 2000, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[172]  R. Zubler Antigens, T Dependent and Independent , 1998 .

[173]  B. Seckler,et al.  Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. , 1998, Chest.

[174]  A. Pasternack,et al.  Intravenous calcitriol therapy restores reduced antigen-induced T-lymphocyte response in 1,25-(OH)2D3-deficient hemodialysis patients. , 1996, Nephron.

[175]  G. Stein,et al.  Influence of recombinant human erythropoietin therapy on in vivo chemotaxis and in vitro phagocytosis of polymorphonuclear cells of hemodialysis patients. , 1996, Blood purification.

[176]  M. Fujishima,et al.  Cellular immunity in hemodialysis patients: a quantitative analysis of immune cell subsets by flow cytometry. , 1995, American journal of nephrology.

[177]  D. Satcher Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[178]  E. Vonesh,et al.  Nutritional status in the elderly patient with uraemia. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[179]  G. Lonnemann,et al.  The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. , 1994, Nephron.

[180]  J. Maciejewski,et al.  Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[181]  J. Riancho,et al.  Vitamin D therapy modulates cytokine secretion in patients with renal failure. , 1993, Nephron.

[182]  C. Baldamus,et al.  Signalling via the TCR/CD3 antigen receptor complex in uremia is limited by the receptors number. , 1993, Nephron.

[183]  W. Hörl,et al.  Uremia and infection: mechanisms of impaired cellular host defense. , 1993, Nephron.

[184]  M. Oppermann,et al.  Gene expression of interleukin-1 beta during hemodialysis. , 1993, Kidney international.

[185]  M. Egidi,et al.  The effect of transfusions on renal allograft survival in the cyclosporine era: a single center report. , 1993, Clinical transplantation.

[186]  H. DeLuca,et al.  1 alpha, 25-Dihydroxyvitamin D3 and 19-nor-1 alpha, 25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. , 1993, Biochimica et biophysica acta.

[187]  M. Singh,et al.  The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients. , 1992, Journal of medicine.

[188]  B. Kristal,et al.  Regulation of interleukin-2 and interferon-gamma gene expression in renal failure. , 1991, Kidney international.

[189]  J. Riancho,et al.  Effect of physiological concentrations of calcitriol on lymphocyte proliferation in normal subjects and in patients with renal failure. , 1990, Nephron.

[190]  J. Berden,et al.  Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE. , 1990, The American journal of medicine.

[191]  M. Goldman,et al.  Bacterial infections in chronic hemodialysis patients: epidemiologic and pathophysiologic aspects. , 1990, Advances in nephrology from the Necker Hospital.

[192]  P. Fondu,et al.  Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[193]  S. Chouaib,et al.  Prostaglandins E as modulators of the immune response. , 1988, Lymphokine research.

[194]  S. Lewis,et al.  Alterations in chemotactic factor-induced responses of neutrophils and monocytes from chronic dialysis patients. , 1988, Clinical nephrology.

[195]  T. Shoji,et al.  In vivo effect of 1 alpha-hydroxyvitamin D3 on interleukin-2 production in hemodialysis patients. , 1988, Nephron.

[196]  K. zum Büschenfelde,et al.  Active hepatitis B vaccination of dialysis patients and medical staff. , 1984, Kidney international.

[197]  L. Moore,et al.  Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. , 1983, Kidney international. Supplement.

[198]  F. Valderrábano,et al.  Transfusion-induced anergy: skin test as an index for pretransplant transfusions. , 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[199]  R. Coppo,et al.  Effects of blood transfusion on cellular immunity. , 1981, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[200]  J. Jervell,et al.  Influence of blood transfusions on kidney transplant and uremic patient survival. , 1977, Scandinavian journal of urology and nephrology. Supplementum.